Assertio Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Assertio Therapeutics (ASRT) Misses Q3 EPS by 10c, Revenues Beat
November 6, 2020 6:17 AM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of ($0.09), $0.10 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $34.57 million versus the consensus estimate of $32.5 million.
Reported Net Product Sales of $34.3 MillionNon-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force IntegrationProvides Updated Outlook for Remainder of 2020We are proud of what we have achieved so far this year, as we... More



